Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
49 studies found for:    "Camurati-Engelmann disease" [DISEASE] OR NCT00001754 [ID-NUMBER]
Show Display Options
Rank Status Study
21 Completed Phase II Study of Lucanix™ in Patients With Stages II-IV Non-Small Cell Lung Cancer
Conditions: Lung Neoplasm;   Carcinoma, Bronchogenic
Intervention: Biological: Lucanix
22 Recruiting Tumor Infiltrating Lymphocytes (TIL) Transduced With TGFbDNRII
Condition: Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Fludarabine monophosphate;   Biological: T-Cells;   Drug: Interleukin-2 (IL-2);   Behavioral: Questionnaires
23 Completed
Has Results
Study of TG-C in Patients With Grade 3 Degenerative Joint Disease of the Knee
Condition: Osteoarthritis, Knee
Interventions: Biological: TissueGene-C;   Drug: Normal Saline
24 Completed Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma
Conditions: Carcinoma, Renal Cell;   Melanoma
Interventions: Biological: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody;   Biological: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ ) Monoclonal Antibody
25 Completed Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma)
Condition: Renal Cell Carcinoma
Intervention: Drug: Anti-Transforming Growth Factor-beta (GC 1008)
26 Unknown  PF-03446962 in Relapsed or Refractory Urothelial Cancer
Condition: Transitional Cell Carcinoma of Bladder
Intervention: Drug: PF03446962
27 Active, not recruiting Phase I Dose Escalation Study to Investigate the Safety of ISTH0036 in Subjects With Glaucoma Undergoing Trabeculectomy
Condition: Primary Open Angle Glaucoma
Interventions: Drug: TGF-β2 antisense oligonucleotide;   Procedure: Trabeculectomy
28 Completed Effect of Montelukast on Remodelling Markers in Asthmatic Children
Condition: Asthma
Interventions: Drug: Montelukast;   Drug: placebo
29 Unknown  Corneal Epitheliotropic Factors in Autologous Serum Eye Drops in Nonautoimmune and Stevens-Johnson Syndrome With Dry Eye
Condition: Stevens-Johnson Syndrome
Intervention:
30 Recruiting First in Human Dose Escalation Study of TEW-7197 in Subjects With Advanced Stage Solid Tumors
Condition: Advanced Stage Solid Tumors
Intervention: Drug: TEW-7197
31 Unknown  Enumeration and Function Analysis of Treg Cells in Peripheral Blood of HCC Patients Before and After Ablation Therapy
Condition: Hepatocellular Carcinoma
Intervention: Procedure: radiofrequency ablation
32 Completed Improvement in Scar Appearance Following Injection of Avotermin (Juvista) Into Skin Incisions Made in Healthy Men and Women
Condition: Cicatrix
Interventions: Drug: Avotermin (Juvista);   Drug: Placebo
33 Unknown  Irbesartan and Adhesion Molecules in AF
Condition: Persistent Atrial Fibrillation
Interventions: Drug: irbesartan;   Drug: placebo
34 Recruiting Natural History and Genetics of Food Allergy and Related Conditions
Conditions: Food Allergy;   Loeys-Dietz Syndrome
Intervention:
35 Active, not recruiting Fresolimumab and Radiotherapy in Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Fresolimumab;   Radiation: Radiation Therapy
36 Completed Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals
Conditions: Diabetes Mellitus Type 1;   Diabetes Mellitus Type 2
Intervention: Drug: Sitagliptin (Januvia)
37 Unknown  Prognostic Value of Transforming Growth Factor-Beta 1 in Normal Pressure Hydrocephalus
Condition: Normal Pressure Hydrocephalus
Intervention: Other: CSF collection
38 Completed The Role of Connective Tissue Growth Factor in the Development of Kidney Disease After Organ Transplantation
Condition: Kidney Transplantation
Intervention:
39 Completed
Has Results
Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)
Conditions: Fibrosis;   Focal Glomerulosclerosis;   Kidney Failure;   Nephrotic Syndrome;   Proteinuria
Intervention: Drug: Pirfenidone
40 Completed A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer
Conditions: Breast Cancer;   Breast Neoplasms
Intervention: Drug: fenretinide

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-49) Show next page of results    Last Page
Indicates status has not been verified in more than two years